Due to the COVID-19 pandemic, the year 2020 has witnessed unprecedented changes in the practice of medicine and dissemination of treatment advances presented in scientific forums.
The totality of evidence generated from comparative systematic stepwise assessment of HD201 and trastuzumab reference in terms of analytical, pharmacodynamic, pharmacokinetic, and clinical similarity demonstrated the equivalence of HD201 to trastuzumab.
Population-Based, Real-World Data of Neoadjuvant Chemotherapy + Pertuzumab + SB3 in HER2-Positive, Early Breast Cancer
Population-based study results support the use of the neoadjuvant chemotherapy + pertuzumab + trastuzumab biosimilar SB3 treatment regimen in the real-world setting, with responses comparable with those achieved in clinical trials.
Cost-Savings from Conversion from Reference Pegfilgrastim with On-Body Injector Device to Biosimilar Pegfilgrastim-jmdb in DLBCL
Simulation-modeling data demonstrate significant cost-savings by converting from reference pegfilgrastim with on-body injector to biosimilar pegfilgrastim-jmdb for prophylaxis of chemotherapy-induced neutropenia/febrile neutropenia in patients with diffuse large B-cell lymphoma (DLBCL).
Pharmacokinetic and Safety Equivalence Demonstrated Between HD204, a Biosimilar of Bevacizumab, in Healthy Male Subjects
The results of a phase 1 pharmacokinetic and safety equivalence study demonstrated equivalence between HD204 and both bevacizumab-EU and bevacizumab-US in healthy males.
Utilization and Adherence Among Infliximab Biosimilar Initiators in a US National Commercial Insurance Database
Real-world national commercial administrative data showed that treatment adherence to infliximab biosimilar is high among patients who were infliximab-naïve, as well as those who had long exposure to infliximab.
US Oncologists’ Perception of the Efficacy, Safety, and Willingness to Prescribe Biosimilar Cancer Therapies
The findings of an online, cross-sectional survey indicate oncologists were less likely to prescribe biosimilars if their practice could lose money and control of the drug, despite clinical safety and efficacy between the biosimilar and originator.
Real-world data indicate treatment adherence was highest among patients who had prior infliximab exposure but no prior infliximab biosimilar use.
Outcomes in Patients with IBS Who Initiate or Switch to the Infliximab Biosimilar Infliximab-dyyb (ONWARD Study)
Real-world data from the ONWARD study indicate that patients with inflammatory bowel syndrome (IBS) who initiate or switch to infliximab-dyyb achieve significant improvement of clinical outcomes and quality of life.
Real-World Comparison of Reference Infliximab versus the Biosimilar Infliximab-abda in Inflammatory Bowel Disease
Data from a large, nationwide, observational cohort study demonstrate that switching from reference infliximab to biosimilar infliximab-abda in patients with inflammatory bowel disease was safe and efficacious compared with continuing reference infliximab.
Page 1 of 4
Results 1 - 10 of 33
Results 1 - 10 of 33